HCW Biologics Inc
HCWB1.490USD
-0.067-4.30%
收盘 12/24, 13:00（美东）报价延迟15分钟
3.91M总市值
亏损市盈率 TTM
关于 HCW Biologics Inc 公司
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
HCW Biologics Inc简介
公司代码HCWB
公司名称HCW Biologics Inc
上市日期Jul 20, 2021
CEOWong (Hing C)
员工数量36
证券类型Ordinary Share
年结日Jul 20
公司地址2929 N Commerce Pkwy
城市MIRAMAR
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33025
电话19548422024
网址https://hcwbiologics.com/
公司代码HCWB
上市日期Jul 20, 2021
CEOWong (Hing C)
HCW Biologics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Wong (Hing C)
18.88%
DRW Securities, LLC
3.09%
Byam (Rebecca)
1.59%
Garrett (Scott T)
0.94%
The Vanguard Group, Inc.
0.57%
其他
74.93%
持股股东
持股股东
占比
Wong (Hing C)
18.88%
DRW Securities, LLC
3.09%
Byam (Rebecca)
1.59%
Garrett (Scott T)
0.94%
The Vanguard Group, Inc.
0.57%
其他
74.93%
股东类型
持股股东
占比
Individual Investor
21.96%
Investment Advisor
4.03%
Investment Advisor/Hedge Fund
0.41%
Research Firm
0.07%
Hedge Fund
0.06%
其他
73.47%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
35
36.93K
1.72%
-55.99K
2025Q2
40
613.16K
31.10%
+79.16K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Wong (Hing C)
509.96K
23.7%
+108.61K
+27.06%
May 16, 2025
Byam (Rebecca)
43.01K
2%
+8.46K
+24.49%
May 12, 2025
Garrett (Scott T)
25.50K
1.19%
+18.81K
+280.84%
May 16, 2025
Golden State Wealth Management, LLC
10.00K
0.46%
+10.00K
--
Jun 30, 2025
Flowers (Lee)
5.72K
0.27%
+962.00
+20.23%
May 08, 2025
Winer (Gary M)
4.08K
0.19%
+3.65K
+858.82%
May 16, 2025
Greene (Rick Scott)
2.07K
0.1%
+962.00
+87.14%
May 12, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 01, 2025
Merger
40→1
公告日期
类型
比率
Apr 01, 2025
Merger
40→1
常见问题
HCW Biologics Inc的前五大股东是谁？
HCW Biologics Inc 的前五大股东如下：
Wong (Hing C)持有股份：509.96K，占总股份比例：23.70%。
Byam (Rebecca)持有股份：43.01K，占总股份比例：2.00%。
Garrett (Scott T)持有股份：25.50K，占总股份比例：1.19%。
Golden State Wealth Management, LLC持有股份：10.00K，占总股份比例：0.46%。
Flowers (Lee)持有股份：5.72K，占总股份比例：0.27%。
Wong (Hing C)持有股份：509.96K，占总股份比例：23.70%。
Byam (Rebecca)持有股份：43.01K，占总股份比例：2.00%。
Garrett (Scott T)持有股份：25.50K，占总股份比例：1.19%。
Golden State Wealth Management, LLC持有股份：10.00K，占总股份比例：0.46%。
Flowers (Lee)持有股份：5.72K，占总股份比例：0.27%。
HCW Biologics Inc的前三大股东类型是什么？
HCW Biologics Inc 的前三大股东类型分别是：
Wong (Hing C)
DRW Securities, LLC
Byam (Rebecca)
Wong (Hing C)
DRW Securities, LLC
Byam (Rebecca)
有多少机构持有HCW Biologics Inc(HCWB)的股份？
截至2025Q3，共有35家机构持有HCW Biologics Inc的股份，合计持有的股份价值约为36.93K，占公司总股份的1.72%。与2025Q2相比，机构持股有所增加，增幅为-29.39%。
哪个业务部门对HCW Biologics Inc的收入贡献最大？
在--，--业务部门对HCW Biologics Inc的收入贡献最大，创收--，占总收入的--%。
